Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics

Table 2 Comparison of binding affinities of amyloid-beta (Aβ) immunotherapies in development for Aβ monomer, soluble Aβ oligomers, and fibrillar Aβ

^aBased on published patent applications or peer-reviewed scientific publications. +, low affinity binding; ++, moderate affinity binding; +++, high affinity binding; -, very low affinity or no binding.

ISSN: 1758-9193